Amgen Inc AMGN

NASDAQ US Health Care Biotechnology

$385.16 ▼ -0.64% ($-2.48)

Index member: S&P 500 Dow Jones

📅 Earnings This Week

Open $382.00

Prev Close $387.64

Day Range $379.34 – $386.82

52W Range $269.77 – $398.00

Market Cap $209.21B

P/E (TTM) 26.47

Beta 0.42

Div Yield 2.60%

EPS (TTM) $14.38

📋 Company Profile

Industry	Biotechnology
Sector	Health Care
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1983-06-17
Shares Out.	539,710,000
Website	amgen.com/ ↗
Phone	18009279800
Employees	31,500
Revenue	$8.62B
Gross Profit	$5.87B
Net Income	$1.82B
Free Cash Flow	$8.60B
Total Assets	$92.50B
Total Liabilities	$83.31B
Equity	$9.19B

About Amgen Inc

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen Inc is a publicly traded company under the ticker symbol AMGN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.